In contrast, in advanced HCC and metastatic disease, ClpP is frequently overexpressed and represents a therapeutic vulnerability that can be targeted by small-molecule activators such as ONC206 and ONC212 (Figure 6) [26,39]. This evidence concerns the gene CLPP and metastatic neoplasm.